Dr. Thomas Patrick O'rourke, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 700 Willow St Ste 203, Vincennes, IN 47591 Phone: 812-882-1000 Fax: 812-882-1004 |
Dr. Thalia Raya Pachiyannakis, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 328 N 2nd St, Suite 205, Vincennes, IN 47591 Phone: 812-882-1000 Fax: 812-882-1004 |
Dr. Shalin Arnett, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 700 Willow St Ste 201, Vincennes, IN 47591 Phone: 812-885-8030 Fax: 812-885-8031 |
Dustin Patrick Blackwell, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 700 Willow St Ste 203, Vincennes, IN 47591 Phone: 812-882-1000 Fax: 812-882-1004 |
News Archive
GE Healthcare today announced the first seven markets where Vizamyl (Flutemetamol F18 injection), a radioactive diagnostic agent approved by the FDA will be available. Late in the second quarter of 2014, Vizamyl will be available to imaging centers near East Rutherford, NJ, Woburn, MA, Beltsville, MD, East Lansing, MI, Dallas, TX, Phoenix, AZ and Colton, CA.
New research, led by scientists at the University of Nottingham, suggests that the environment in which men live may affect their reproductive health.
Silicon Biosystems, S.p.A., a provider of specialized molecular and cell biology technology, today announced that it has formed a U.S. subsidiary operation, Silicon Biosystems, Inc., to be headquartered in San Diego, California. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company's DEPArray™ technology platform.
HealthPartners programs designed to improve the quality and efficiency of care reduced medical expenses by more than $137 million last year, according to the organization's 2009 Return on Investment report.
ImpactRx® announced today that the company has executed a Series E round of financing in the amount of $1.2 million, of which the first tranche of $678,040 was closed on December 23, 2009. ImpactRx is the pioneering force in measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation's highest value physicians.
› Verified 1 days ago